Loading
A phase 3 trial of Abiraterone acetate and Prednisone in Prostate cancer, run by Janssen Research & Development, LLC, completed.
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate is a phase 3 interventional study registered as NCT01517802 by Janssen Research & Development, LLC, with 32 participants recorded, started 2012-03-28 and reaching its primary completion in 2021-04-22. Interventions recorded: Abiraterone acetate, Prednisone. Conditions recorded: Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer.
Linked to the idea "Prescribe a quarter dose of abiraterone with breakfast" because the registry names Abiraterone acetate and Prednisone among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
32 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2022-05-10), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs)primary | Abiraterone Acetate + Prednisone/Prednisolone | 31 | 16 participants | - | - | link |
Shares Prescribe a quarter dose of abiraterone with breakfast, Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.